Novo plans 5+ blockbuster drug launches by 2030: 5 things to know
Novo Nordisk unveiled its 2030 strategic targets at a Capital Markets Day in London Sept. 21, aiming to reassure investors it can navigate looming patent expirations for semaglutide, the active ingredient in Ozempic and Wegovy, according to a Sept. 21 report from the Financial Times. Here are five things to know: The post Novo plans 5+ blockbuster drug launches by 2030: 5 things to know appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.